Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer IntfiledCriticalFerrer Int
Priority to UY30249ApriorityCriticalpatent/UY30249A1/en
Publication of UY30249A1publicationCriticalpatent/UY30249A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La invencinn proporciona novedades imidazo [1,2-b]piridazinas de fnrmula (I) y sales, polimorfos, hidratos, tautnmeros, solvatos y estereoisnmeros farmaccuticamente aceptables de las mismas.Los compuestos de fnrmula (I) son utiles para el tratamiento y la prevencinn de enfermedades asociadas con la modulacinn del receptor GABAa, ansiedad, epilepsia, trastornos del sueno incluyendo insomnio, y para la induccinn de sedacinn-hipnosis, anestesia, sueno y relajacinn muscular. La invencinn tambicn proporciona procedimientos sintcticos para la peparacinn de dichos compuestos y ciertos intermediarios, ase como los propios intermediarios.The invention provides novelties imidazo [1,2-b] pyridazines of formula (I) and pharmacologically acceptable salts, polymorphs, hydrates, tautomers, solvates and stereoisomers thereof. The compounds of formula (I) are useful for the treatment and prevention of diseases associated with GABAa receptor modulation, anxiety, epilepsy, sleep disorders including insomnia, and for the induction of sedation-hypnosis, anesthesia, sleep and muscle relaxation. The invention also provides synthetic methods for the preparation of said compounds and certain intermediates, as well as the intermediaries themselves.
Compounds derived from 1,2,4-triazolo [4,3-a] pyridine, positive allosteric modulators of mglur2 receptors; pharmaceutical composition; process to prepare it; and its use in the treatment or prevention of a central nervous system disorder such as anxiety, schizophrenia and migraine, among others.
Imidazo [1,2-b] pyridazine derivative compounds, pde10 inhibitors; pharmaceutical composition; preparation procedure; Useful for the treatment or prevention of a CNS disorder, such as psychotic, anxiety, movement, mood, neurodegenerative, metabolic and pain disorders, among others.
SUBSTITUTED AMIDES OF TIENOPIRROLCARBOXYL ACID, AMIDAS OF THE PYRROLOTIAZOLCARBOXYL ACID AND RELATED ANALOGS AS INHIBITORS OF CASEINE CINASE IE (EPSILON)